The European Court of Justice ("ECJ") has issued a ruling that when a directive relating to the pricing of human medicines requires the removal of a drug from compulsory health insurance, the directive must explain the rationale for that decision. According to the ECJ, the obligation to disclose this information will allow interested parties to verify whether pricing decisions discriminate between national medicinal products and those originating in other Member States.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.